- Company
- Xeljanz to be used with caution in thrombosis patients
- by Nho, Byung Chul Mar 30, 2020 06:18am
- Among the indications for Pfizer's JAK inhibitor Xeljanz (Tofacitinib citrate), the standard for 10 mg high dose prescription of ulcerative colitis has changed. Pfizer recently changed the permission, and added that patients with risk factors for thrombosis should avoid using this drug and patients with signs·symptoms of thrombosis should
- InterView
- Law firm's entry into the pharmaceuticals is just beginning
- by Kim, Jin-Gu Mar 30, 2020 06:18am
- The role of law firms has recently grown in the pharmaceutical bio industry. Some process was through law firms. Kim & Chang, Lee & Ko, Yulchon, HMP Law, and LK Partners are expanding their business areas in the healthcare field. The most prominent law firm is Lee & Ko. The overall evaluation is that, in terms of the health care team members,
- Policy
- Rapid support to develop COVID-19 vaccines & treatments
- by Kim, Jung-Ju Mar 29, 2020 11:19pm
- The government said it was moving rapidly to support R&D for the development of 'COVID-19' vaccine and exclusive treatment. Taeho Yoon, the director of Disinfection, the Central Disaster Management Headquarters (Public Health Policy Officer, the MOHW) today (25th) morning after the video conference about COVID-19/the central disaster and s
- Company
- SK nabs approval for cilostazol-ginko combination SR drug
- by Lee, Seok-Jun Mar 29, 2020 11:19pm
- On Mar. 25, SK Chemicals has announced the Korean health authority has approved sustained release tablet version of antiplatelet drug Renexin. Renexin is a combination drug consisting of antiplatelet agent cilostazol (200 mg) and ginko biloba extract (160 mg). The combination drug, with cilostazol and ginko biloba extract inhibiting p
- Company
- Lipitor and Vytorin to be priced lower than generic?
- by Eo, Yun-Ho Mar 29, 2020 11:18pm
- An odd phenomenon of the original’s pricing dipping down to 85 percent of the lowest generic pricing may actually happen in Korea. The stepped drug pricing system coming in effect from July prices same-substance drugs under differentiated pricing depending on drugs meeting two qualifying standards. But from 21st same-substance drug, the
- Policy
- Gangnam Severance to test chloroquine preventing COVID-19
- by Lee, Tak-Sun Mar 29, 2020 11:18pm
- Gangnam Severance Hospital is to conduct a research-purpose clinical trial on malaria drug hydroxychloroquine to test its preventive effect, as it is currently used on patients with COVID-19. On Mar. 25, Korea’s Ministry of Food and Drug Safety (MFDS) approved the clinical trial protocol on a ‘Study on Hydroxychloroquine’s Post-exposur
- Policy
- “Lowest A7 price for latecommer PE-exempted RSA drug”
- by Lee, Hye-Kyung Mar 29, 2020 11:18pm
- When a first-in-class drug is listed with risk sharing agreement (RSA), a follow-on pharmacoeconomic evaluation (PE)-exempted drug would be reviewed for reimbursement feasibility with price higher than the lowest A7-adjusted price. And the revised review criteria added a phrase, ‘only referring to drugs with public health insurance reimburs
- Policy
- “NA should stop loosening new drug regulation”
- by Lee, Jeong-Hwan Mar 29, 2020 11:17pm
- Prior to the upcoming general election, health related civic groups are voicing out to the National Assembly (NA) about their disapproval on over-the-counter (OTC) drug sold outside of pharmacy and profit-making pharmacy. The groups urged the lawmakers to establish public pharmaceutical company, learning from COVID-19 outbreak, and sto
- Opinion
- [Reporter’s view] Social distance is urgently needed
- by Lee, Hye-Kyung Mar 29, 2020 11:17pm
- The government has nailed down the 15-day period from March 22 to April 5 as a decisive time to win the war against COVID-19. On the 21st, Prime Minister Sye-kyun Chung said, “We need a much stronger social distance” through the dialogue with the public. In fact, the government's policy is a bit late. The government emphasizes social dis
- Company
- Novartis vs. Hanmi: Galvus generic to ignite legal dispute
- by Eo, Yun-Ho Mar 26, 2020 06:12am
- A conflict between Novartis and Hanmi Pharmaceutical is expected to deepen over the generic of the DDP-4 inhibitor Galvus. Novartis Korea is apparently preparing legal actions against Korean pharmaceutical companies attempting to evade patent infringement on Galvus (vildagliptin) by excluding one indication. The legal dispute over the
